| Literature DB >> 24595189 |
Daniel J Friedman1, Na Wang, James B Meigs, Udo Hoffmann, Joseph M Massaro, Caroline S Fox, Jared W Magnani.
Abstract
BACKGROUND: Obesity is associated with altered atrial electrophysiology and a prominent risk factor for atrial fibrillation. Body mass index, the most widely used adiposity measure, has been related to atrial electrical remodeling. We tested the hypothesis that pericardial fat is independently associated with electrocardiographic measures of atrial conduction. METHODS ANDEntities:
Keywords: atrium; conduction; electrocardiography; epidemiology; obesity
Mesh:
Year: 2014 PMID: 24595189 PMCID: PMC4187474 DOI: 10.1161/JAHA.113.000477
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1.Measurement of (A) PR interval, (B) P wave duration, (C) P wave amplitude, (D) P wave area, and (E) P wave terminal force.
Baseline Characteristics
| Characteristics | Overall (N=1946) | Women (N=879) | Men (N=1067) |
|---|---|---|---|
| Age, y | 45.0±6.2 | 46.2±5.7 | 44.0±6.4 |
| Current smoking | 288 (14.8) | 126 (14.3) | 162 (15.2) |
| Heavy drinking | 251 (13) | 102 (11.7) | 149 (14.2) |
| Systolic blood pressure, mm Hg | 119±14 | 117±16 | 121±13 |
| Diastolic blood pressure, mm Hg | 77±9 | 74±9 | 79±9 |
| Waist circumference, cm | 95.4±14.4 | 90.4±15.4 | 99.5±11.9 |
| Body mass index, kg/m2 | 27.4±5.3 | 26.5±5.9 | 28.2±4.5 |
| Heart rate, beats per minute | 62±10 | 63±10 | 61±10 |
| Weight, kg | 81.1±18.2 | 71.3±16.6 | 89.2±15.2 |
| AV nodal medications | 132 (6.8) | 62 (7.1) | 70 (6.6) |
| Prevalent hypertension | 411 (21.1) | 148 (16.8) | 263 (24.6) |
| Diabetes | 71 (3.6) | 24 (2.7) | 47 (4.4) |
| Hormone replacement treatment | 85 (9.7) | — | |
| Post‐menopausal | 221 (25.1) | — | |
| Pericardial fat, cm3 | 105±38 | 92±34 | 116±38 |
| Visceral fat, cm3 | 1603±920 | 1127±718 | 1995±882 |
| Intrathoracic fat, cm3 | 88±60 | 52±32 | 117±61 |
| PR interval, ms | 160 (140 to 170) | 150 (140 to 160) | 160 (150 to 180) |
| P wave duration, ms | 104 (98 to 112) | 102 (94 to 110) | 108 (100 to 114) |
| P wave amplitude, μV | 112 (92 to 131) | 112 (92 to 136) | 110 (92 to 126) |
| P wave area, μV·ms | 307 (248 to 365) | 308 (238 to 367) | 307 (252 to 363) |
| P wave terminal force, μV·ms | 1488 (0 to 2457) | 1368 (0 to 2340) | 1584 (0 to 2584) |
Continuous measures are mean±SD and categorical measures No (%). Heavy alcohol consumption is defined as ≥15 drinks per week in men and ≥8 drinks per week in women. Atrioventricular (AV) nodal medications include beta‐blockers, calcium channel blockers (dihydropyridine and non‐dihydropyridine), cardiac glycosides, and Class I and III antiarrhythmic medications. P wave indices: expressed as median (Q1 to Q3).
Age and Sex Adjusted Pearson Partial Correlation Coefficients Relating P Wave Indices and Adipose Measures
| PR Interval (N=1944) | P Wave Duration (N=1911) | P Wave Amplitude (N=1911) | P Wave Area (N=1911) | P Wave Terminal Force (N=1909) | |
|---|---|---|---|---|---|
| WC | 0.06‡ | 0.21* | −0.04 | 0.03 | 0.19* |
| BMI | 0.07† | 0.20* | −0.06‡ | 0.01 | 0.20* |
| Pericardial fat | −0.01 | 0.15* | −0.04 | 0.02 | 0.17* |
| Visceral fat | 0.02 | 0.15* | −0.07† | −0.01 | 0.21* |
| Intrathoracic fat | −0.002 | 0.13* | −0.07† | −0.01 | 0.17* |
P wave indices as defined by text. BMI indicates body mass index; WC, waist circumference.
*P<0.0001, †P<0.01, †P<0.05.
P Values for Sex‐Specific Interactions in the Multivariable‐Adjusted* Relations Between P Wave Indices and Adipose Measures
| Adipose Variable | PR Interval | P Wave Duration | P Wave Amplitude | P Wave Area | P Wave Terminal Force |
|---|---|---|---|---|---|
| Waist circumference | 0.54 | 0.48 | 0.41 | 0.14 | 0.050 |
| Body mass index | 0.66 | 0.20 | 0.45 | 0.041 | 0.042 |
| Pericardial fat | 0.12 | 0.042 | 0.029 | 0.010 | 0.051 |
| Visceral fat | 0.29 | 0.002 | 0.89 | 0.17 | 0.007 |
| Intrathoracic fat | 0.41 | 0.001 | 0.48 | 0.39 | <0.001 |
Multivariable adjustment includes, age, heart rate, systolic and diastolic blood pressures, AV nodal medications (beta‐blocker, dihydropyridine and non‐dihydropyridine calcium channel blockers, cardiac glycosides, Class I and III antiarrhythmic medications), hormone replacement therapy, prevalent hypertension or hypertension treatment, diabetes, and menopausal status in women.
Sex‐Stratified Multivariable* Models of Pericardial Fat and P Wave Indices With Additional Adjustment (+) for Visceral Fat, Intrathoracic Fat, and BMI
| Model | Adipose Variable Measures | Women | Male | ||||
|---|---|---|---|---|---|---|---|
| Beta | SE | Beta | SE | ||||
|
| |||||||
| Pericardial fat | Pericardial | 1.7 | 0.9 | 0.049 | −0.2 | 0.7 | 0.82 |
| +Visceral fat | Pericardial | 0.6 | 1.0 | 0.59 | −1.1 | 0.8 | 0.18 |
| Visceral | 2.4 | 1.3 | 0.06 | 2.1 | 0.9 | 0.023 | |
| +Intrathoracic fat | Pericardial | 1.5 | 1.1 | 0.18 | −0.8 | 0.9 | 0.35 |
| Intrathoracic | 0.5 | 1.9 | 0.78 | 1.2 | 0.8 | 0.17 | |
| +BMI | Pericardial | 0.5 | 0.9 | 0.58 | −1.3 | 0.8 | 0.09 |
| BMI | 2.2 | 0.8 | 0.005 | 3.5 | 0.9 | <0.001 | |
|
| |||||||
| Pericardial fat | Pericardial | 2.3 | 0.4 | <0.001 | 1.2 | 0.4 | 0.002 |
| +Visceral fat | Pericardial | 1.4 | 0.5 | 0.009 | 1.0 | 0.4 | 0.033 |
| Visceral | 2.1 | 0.7 | 0.002 | 0.5 | 0.5 | 0.28 | |
| +Intrathoracic fat | Pericardial | 1.5 | 0.6 | 0.009 | 1.0 | 0.5 | 0.030 |
| Intrathoracic | 2.3 | 1.0 | 0.018 | 0.4 | 0.5 | 0.43 | |
| +BMI | Pericardial | 1.3 | 0.5 | 0.005 | 0.7 | 0.4 | 0.08 |
| BMI | 1.8 | 0.4 | <0.001 | 1.5 | 0.5 | 0.002 | |
|
| |||||||
| Pericardial fat | Pericardial | −1.1 | 1.3 | 0.38 | −3.2 | 0.9 | <0.001 |
| +Visceral fat | Pericardial | 3.0 | 1.6 | 0.06 | −2.1 | 1.0 | 0.043 |
| Visceral | −8.9 | 1.9 | <0.001 | −2.5 | 1.1 | 0.029 | |
| +Intrathoracic fat | Pericardial | 2.6 | 1.7 | 0.12 | −2.0 | 1.1 | 0.06 |
| Intrathoracic | −10.1 | 2.9 | <0.001 | −2.2 | 1.0 | 0.037 | |
| +BMI | Pericardial | 1.1 | 1.4 | 0.45 | −2.7 | 1.0 | 0.005 |
| BMI | −4.2 | 1.2 | <0.001 | −1.6 | 1.1 | 0.16 | |
|
| |||||||
| Pericardial fat | Pericardial | 4.7 | 3.7 | 0.21 | −5.6 | 2.9 | 0.06 |
| +Visceral fat | Pericardial | 11.3 | 4.5 | 0.012 | −1.6 | 3.4 | 0.64 |
| Visceral | −14.4 | 5.6 | 0.010 | −8.7 | 3.7 | 0.020 | |
| +Intrathoracic fat | Pericardial | 10.5 | 4.8 | 0.029 | −2.8 | 3.5 | 0.43 |
| Intrathoracic | −15.6 | 8.3 | 0.06 | −5.1 | 3.4 | 0.14 | |
| +BMI | Pericardial | 7.2 | 4.1 | 0.08 | −3.7 | 3.2 | 0.25 |
| BMI | −4.6 | 3.4 | 0.17 | −5.9 | 3.7 | 0.10 | |
|
| |||||||
| Pericardial fat | Pericardial | 297.3 | 51.5 | <0.001 | 160 | 51.1 | 0.002 |
| +Visceral fat | Pericardial | 140.9 | 61.9 | 0.023 | 84.2 | 59.1 | 0.15 |
| Visceral | 339.8 | 76.6 | <0.001 | 164.4 | 64.9 | 0.011 | |
| +Intrathoracic fat | Pericardial | 117.2 | 66.2 | 0.08 | 104.1 | 60.8 | 0.09 |
| Intrathoracic | 483.3 | 113.3 | <0.001 | 100.2 | 59.3 | 0.09 | |
| +BMI | Pericardial | 169.6 | 56.4 | 0.003 | 127.9 | 55.1 | 0.020 |
| BMI | 239.3 | 46 | <0.001 | 98.1 | 63.6 | 0.12 | |
BMI indicates body mass index; SE, standard error.
Multivariable models adjusted for indicated adiposity measures and age, heart rate, systolic and diastolic blood pressures, AV nodal medications (beta‐blocker, dihydropyridine and non‐dihydropyridine calcium channel blockers, cardiac glycosides, Class I and III antiarrhythmic medications), hormone replacement therapy in women, prevalent hypertension or hypertension treatment, diabetes, and menopausal status in women.
Figure 2.Sex‐stratified cubic restricted splines depicting the association of pericardial fat and (A) P wave duration, (B) P wave terminal force, (C) PR interval, (D) P wave amplitude, and (E) P wave area. Dotted lines represent 95% confidence intervals surrounding the estimate.
The Association of P Wave Indices and Adiposity Measures in Sex‐Stratified, Multivariable‐Adjusted* Analyses
| Adipose Variable | Women | Men | ||||
|---|---|---|---|---|---|---|
| β | SE | β | SE | |||
| PR interval | ||||||
| Waist circumference | 2.4 | 0.7 | 0.001 | 3.0 | 0.9 | <0.001 |
| BMI | 2.3 | 0.7 | <0.001 | 3.0 | 0.8 | <0.001 |
| Pericardial fat | 1.7 | 0.9 | 0.049 | −0.2 | 0.7 | 0.82 |
| Visceral fat | 2.8 | 1.1 | 0.007 | 1.5 | 0.8 | 0.07 |
| Intrathoracic fat | 2.1 | 1.5 | 0.14 | 0.7 | 0.7 | 0.31 |
| P wave duration | ||||||
| Waist circumference | 2.5 | 0.4 | <0.001 | 2.2 | 0.5 | <0.001 |
| BMI | 2.3 | 0.4 | <0.001 | 1.8 | 0.4 | <0.001 |
| Pericardial fat | 2.3 | 0.4 | <0.001 | 1.2 | 0.4 | 0.002 |
| Visceral fat | 3.0 | 0.5 | <0.001 | 1.1 | 0.4 | 0.013 |
| Intrathoracic fat | 3.9 | 0.8 | <0.001 | 0.9 | 0.4 | 0.020 |
| P wave amplitude | ||||||
| Waist circumference | −3.6 | 1.1 | 0.001 | −2.5 | 1.1 | 0.020 |
| BMI | −3.8 | 1.1 | <0.001 | −2.8 | 1.0 | 0.008 |
| Pericardial fat | −1.1 | 1.3 | 0.38 | −3.2 | 0.9 | <0.001 |
| Visceral fat | −6.8 | 1.6 | <0.001 | −3.6 | 1.0 | <0.001 |
| Intrathoracic fat | −7.2 | 2.2 | 0.001 | −3.2 | 0.9 | <0.001 |
| P wave area | ||||||
| Waist circumference | −0.9 | 3.2 | 0.78 | −4.1 | 3.6 | 0.24 |
| BMI | −2.1 | 3.0 | 0.49 | −7.5 | 3.4 | 0.027 |
| Pericardial fat | 4.7 | 3.7 | 0.21 | −5.6 | 2.9 | 0.06 |
| Visceral fat | −6.4 | 4.6 | 0.16 | −9.6 | 3.2 | 0.003 |
| Intrathoracic fat | −4.1 | 6.4 | 0.52 | −6.5 | 2.9 | 0.023 |
| P wave terminal force | ||||||
| Waist circumference | 297.7 | 44.6 | <0.001 | 134.3 | 61.7 | 0.030 |
| BMI | 299.7 | 41.6 | <0.001 | 153.9 | 59.1 | 0.009 |
| Pericardial fat | 297.3 | 51.5 | <0.001 | 160.0 | 51.1 | 0.002 |
| Visceral fat | 439.0 | 63.2 | <0.001 | 211.3 | 56.0 | <0.001 |
| Intrathoracic fat | 611.3 | 87.4 | <0.001 | 155.5 | 49.8 | 0.002 |
BMI indicates body mass index; SE, standard error.
Multivariable‐adjustment includes age, heart rate, systolic and diastolic blood pressures, AV nodal medications (beta‐blocker, dihydropyridine and non‐dihydropyridine calcium channel blockers, cardiac glycosides, Class I and III antiarrhythmic medications), hormone replacement therapy in women, prevalent hypertension or hypertension treatment, diabetes, and menopausal status in women.